The nation of Zimbabwe has declined a significant American health deal valued at 367 million US dollars (272 million pounds) over five years because of Washington's request for sensitive data.
This move came to light following a official document dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government representative later explained that the US was seeking biological samples for scientific study and commercial purposes while refused to guarantee the resulting advantages from future medical innovations.
"We will now turn to the challenging and unfortunate process of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for continued negotiations to find a agreement agreeable to all parties so the nation's vital HIV programme can continue.
Broader Context
This rejection follows a similar situation in neighbouring Kenya, where a high court blocked a related deal with the US following concerns were filed about the security of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump argued its expenditure was "wasteful" and his government was seeking direct bilateral agreements to enhance openness and accountability.
Based on reports, Sixteen nations in Africa have to date agreed to these new agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation would have delivered extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to provide its biological resources and data indefinitely, with no equivalent promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"Put simply, our nation would provide the raw materials for scientific discovery with no assurance that the resulting innovations would be available to our citizens should a new health crisis arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining systems previously set up through the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential pandemics.
"This mechanism is intended to guarantee that when a nation contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to create them."
These objections regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our US partners on how subsequent co-operation might be designed in a way that respects the sovereignty and interests of each country."
Health Experts Response
Medical experts said it acknowledged the official position, but urged that negotiations should continue given that much of the nation's HIV programmes depended on foreign aid.
"In cases where technical issues arise, such as those relating to information security or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," it said.
The situation emphasises the continuing debate between receiving vital international aid and protecting local interests in an increasingly data-driven world.